Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
Two of the biggest advances in healthcare in the last decade have been the gradual de-stigmatisation of mental health and the increased interest in researching the causes and treatments of
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<